SCHOTT Pharma
Mario Haas has a diverse work experience, primarily within the SCHOTT company. Mario has held various roles including Senior Vice President - Head of Business Segment Drug Delivery Systems at SCHOTT Pharma since 2023. Prior to that, they were the Vice President - Head of Polymer Solutions, Pharmaceutical Systems at SCHOTT from 2014 to 2023. In this role, they had global P&L responsibility and was a member of the SCHOTT Pharmaceutical Systems management team. Mario also served as the Senior Manager Corporate Business Development, Deputy Head New Ventures at SCHOTT from 2014 to 2017. Before joining SCHOTT, Mario Haas was the Head of Strategic Marketing at Overath Gmbh from 2013 to 2014 and the Project Manager Strategy & Business Development SCHOTT Solar at SCHOTT from 2011 to 2012. Mario has also worked at Trocellen Group as the General Manager Marketing and Manager Corporate Marketing, and at Ford Motor Company as a Graduand.
Mario Haas has completed Executive Education at ESMT Berlin, studied Wirtschaftswissenschaften at Bonn-Rhein-Sieg University of Applied Sciences, pursued General Management at Boston Business School, and earned a Six Sigma Green Belt from Ford Motor Company.
This person is not in any offices
SCHOTT Pharma
1 followers
SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world – because human health matters. Every day, more than 4,700 people from 65 nations work at SCHOTT Pharma to contribute to global healthcare. The company has 17 manufacturing sites across major pharmaceutical hubs in Europe, the Americas and Asia. SCHOTT Pharma maintains a diverse portfolio of injectable drug containment and delivery solutions. These solutions range from prefillable glass and polymer syringes, cartridges, vials and ampoules. The company has focused on developing innovations for future technologies by: • Creating over 1000 patents and technologies developed in-house • Building a state-of-the-art Research and Development Center in Switzerland • Absorbing over 130 professionals focused on Research and Development Despite being a pharmaceutical manufacturer, SCHOTT Pharma aims to become climate-neutral by 2030. The company commits to this through sustainable development approaches in the society and the environment. Based in Mainz, Germany, it is part of SCHOTT AG that falls under the Carl Zeiss Foundation. SCHOTT Pharma has over 1700 global customers, 30 of which are the leading pharmaceutical manufacturers of injectable drugs. These customers have generated combined sales of EUR 899 million in the fiscal year 2023. Contact us now: pharma@schott.com Data protection: https://www.schott-pharma.com/en/legal-social